Please assess the completion status of the following clinical trial:

Trial Title: Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-50 yrs~* Normal glucose tolerance during standard oral glucose tolerance test (OGTT)~* Inclusion criteria for bariatric surgery proposed by the 1991 National Institutes of Health Consensus Development Panel Report.~Exclusion Criteria:~* Liver or renal failure, cancer, acute or chronic inflammatory diseases~* Chronic treatment with any type of medications~* organic pituitary deficiency~* Bulimia Nervosa of the DSM-IV~* Ulcers or malignancies excluded by oesophagus-gastro-duodenoscopy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): The clinical examination will determine anthropometric indexes (weight, height, BMI, waist circumference). The biochemical evaluation will include the measurement of lipid profile, fasting plasma glucose and insulin, liver test function, FT3, FT4, GHRH + Arginine test to detect GHD, plasma IGF-I levels. The instrumental evaluation will include DEXA Total Body and bioimpedance analysis to determine body composition, and liver ultrasounds.
- 2 (Type: PLACEBO_COMPARATOR): PHASE II: In the medical treatment protocol very severe obese patients with persistent GHD after LASGB will be inclosed. Starting from 15-day, GHD patients were re-evaluated by GHRH + Arginine test. After evaluation, the patients with persistent GHD will be randomized to be treated with Recombinant GH replacement therapy (Group A: Recombinant GH replacement therapy at the initial dose 0.15-0.30 mg/die; dose adjustment will be made according to IGF-I levels; Group B: no GH treatment).

Based on this trial design, predict the completion outcome and termination type (if applicable).